CN109200089A - 一种明目薰蒸水的制备方法 - Google Patents
一种明目薰蒸水的制备方法 Download PDFInfo
- Publication number
- CN109200089A CN109200089A CN201810990923.4A CN201810990923A CN109200089A CN 109200089 A CN109200089 A CN 109200089A CN 201810990923 A CN201810990923 A CN 201810990923A CN 109200089 A CN109200089 A CN 109200089A
- Authority
- CN
- China
- Prior art keywords
- preparation
- water
- chu chrysanthemum
- fumigation
- improving eyesight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 230000004438 eyesight Effects 0.000 title claims abstract description 21
- 238000003958 fumigation Methods 0.000 title claims abstract description 21
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 53
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 18
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 18
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 18
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 18
- 241000628997 Flos Species 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000006286 aqueous extract Substances 0.000 claims abstract description 13
- 238000012545 processing Methods 0.000 claims abstract description 6
- 241000723353 Chrysanthemum Species 0.000 claims description 52
- 239000000843 powder Substances 0.000 claims description 20
- 239000012153 distilled water Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 241000205585 Aquilegia canadensis Species 0.000 claims description 11
- 229930003944 flavone Natural products 0.000 claims description 11
- 235000011949 flavones Nutrition 0.000 claims description 11
- 239000008236 heating water Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 150000002213 flavones Chemical class 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004327 boric acid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 239000004328 sodium tetraborate Substances 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000003464 asthenopia Diseases 0.000 abstract description 7
- 206010023332 keratitis Diseases 0.000 abstract description 5
- 206010010741 Conjunctivitis Diseases 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 30
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种明目薰蒸水的制备方法,涉及熏蒸水加工技术领域。所述制备方法包括:滁菊提取液的制备、金银花提取液的制备、薄荷水提取液的制备和熏蒸水制备等步骤;本发明克服了现有技术的不足,所制得熏蒸水能有效抑制眼部细菌生长,消除眼部炎症,缓解结膜炎、角膜炎症状,同时达到缓解眼部疲劳、促进眼部血液循环的效果,并且本发明原料易得、制备简单、用途广泛,适用于眼睛保健,医疗辅助治疗和眼疾预防治疗等方面。
Description
技术领域
本发明涉及熏蒸水加工技术领域,具体涉及一种明目薰蒸水的制备方法。
背景技术
目前中国近视人口逐渐增加,国内很多医疗机构、高等学校都在研究新的复方组成和新的给药途径。古代传统中医方剂中洗眼汤成为了当时仅有的眼部给药制剂。由于古代的科学发展具有局限性,对药物制剂的规范化处理欠缺,所以仅有典型的汤剂,散剂、丸剂为主要的剂型。古代的科学与生产水平限制了传统中医药大发展。现代科学水平提高,我们应将传统中医药与现代化技术水平相结合,研发具有划时代意义的现代型中医药产品。现阶段传统的中医药相结合的眼睛保健产品的开发市场处于初级阶段,以中药为原料的薰蒸水市场上鲜有。大多数都是从西医的角度研究某一成分对眼睛各组织部位的药理作用,忽略了传统中药清肝明目的作用与中药配伍对方剂带来的影响。
现在社会由于辐射、用眼过度导致眼疾人数剧增,市场上治疗眼疾的直接眼部给药剂型主要是滴眼液,主要有抗炎抑菌,降低或升高眼内压、舒张或收缩睫状肌的作用。这些作用常用于治疗结膜炎、角膜炎、青光眼、白内障、缓解视力疲劳、术后恢复、抗感染等辅助作用。珍视明滴眼液、左氧氟沙星滴眼液、利福平滴眼液、麝香复方滴眼液等需多次连续使用,常常发生药液染菌或病人发生交叉感染等情况。其生产与实际应用具有一定的容差性,眼科用药合理性与有效性大打折扣。薰蒸水的生产制备流程简单,携带方便,质量可控,结合新式给药仪器与途径保证了用药合理性,使药效得到充分发挥。
发明内容
针对现有技术不足,本发明提供一种明目薰蒸水的制备方法,所制得熏蒸水能有效抑制眼部细菌生长,消除眼部炎症,缓解结膜炎、角膜炎症状,同时达到缓解眼部疲劳、促进眼部血液循环的效果,并且本发明原料易得、制备简单、用途广泛,适用于眼睛保健,医疗辅助治疗和眼疾预防治疗等方面。
为实现以上目的,本发明的技术方案通过以下技术方案予以实现:
一种明目薰蒸水的制备方法,所述制备方法包括以下步骤:
(1)滁菊提取液的制备:选取优质干燥滁菊,于烘干机中进行烘干处理,再将干燥过的滁菊于粉碎机中进行粉碎处理,得滁菊粉,将滁菊粉加入蒸馏水中,采用超声水提法进行黄酮提取,再经抽滤和冷却后得到滁菊提取液;
(2)金银花提取液的制备:将干燥的金银花经研磨机研磨得金银花粗粉,加入15倍体积份数的蒸馏水常温下进行浸泡,后再于水浴加热的情况下浸泡70min,进行抽滤,所得滤渣同条件下再次浸泡抽滤,合并两次所得滤液,将滤液静置后过滤,将滤液浓缩至原加入蒸馏水体积的2/3,得金银花提取液;
(3)薄荷水提取液的制备:取优质薄荷加入10倍体积份数的蒸馏水,在密闭环境下水浴加热保温一段时间,再将其于大火上煮至沸腾,后转小火煎煮,趁热抽滤,所得澄清液为薄荷水提取液;
(4)熏蒸水制备:将滁菊提取液浓缩至金银花提取液等体积后,与金银花提取液和薄荷水提取液混合,加稀氨水调节PH至8.0,再水浴加热除氨水调PH至6.0,后向其中加入硼砂和硼酸,搅拌均匀后,在灭菌锅中灭菌70min,将所得溶液进行分装,即得到本发明明目薰蒸水。
优选的,步骤(1)中滁菊于烘干机中烘干的温度为50℃,烘干时间为1h,滁菊研磨后的粉末需过40目筛。
优选的,滁菊提取液的制备过程中,滁菊进行超声水提取黄酮时,滁菊粉与蒸馏水的料液比为1:27,超声功率为380W,提取温度为50℃,提取时间为55min。
优选的,步骤(2)中金银花粗粉与蒸馏水混合在常温下浸泡的时间为24h,水浴加热的温度为75℃。
优选的,步骤(3)中,水浴加热的温度为70℃,加热的时间为30min,后期小火煎煮的时间为10min。
优选的,步骤(4)中滁菊提取液、金银花提取液、薄荷水提取液、硼砂和硼酸的质量比为20∶20∶10∶1.3∶5。
本发明提供一种明目薰蒸水的制备方法,与现有技术相比优点在于:
(1)本发明采用传统的清肝明目中药如滁菊、金银花、薄荷,作为原料药材提取纯化制备成药液,滁菊具有清热解毒、清肝明目的作用,对治疗眼睛疲劳、视力模糊有很好的疗效;金银花中的绿原酸具有抑菌、抗病毒作用,对治疗细菌性结膜炎、角膜炎等有很好的疗效。薄荷,味辛,性凉;归肺、肝经;清香升散,善清头目之风热,因而能治疗头晕目眩,清利头目。以上三药配伍,以滁菊为君药,清热解毒,清肝明目,缓解眼疲劳,改善眼部血液循环;金银花为臣药,抑制眼部细菌生长,消除眼部炎症,缓解结膜炎、角膜炎症状;薄荷为佐药,升清之性行药势,辅助性缓解眼睛疲劳,改善局部血液循环。
(2)滁菊花中的主要成分为黄酮类化合物,黄酮类化合物具有很多有临床价值的药理作用,如抗肿瘤、抗癌、抗炎镇痛、抗氧化、抗辐射等作用,本发明在滁菊的黄酮萃取过程中,经过正交实验优化水提取滁菊总黄酮的工艺,确定出提取黄酮的最优条件,使本发明薰蒸水原料药液制备的条件稳定可行,且本发明所有成分均为天然中药经水提取而来,所以不仅可以给眼睛用药,还能给皮肤用药,甚至能给口腔用药。面额部及太阳穴喷涂则能消暑醒脑,美颜消斑。口腔给药则能消炎定痛、清喉利咽。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面结合本发明实施例对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
对滁菊进行超声水提法提取黄铜的正交检测:
料液比的选择:设定提取温度50℃,时间20min,超声功率240W,考察料液比1:15、1:20;1:25、1:30、1:35时对滁菊黄酮提取率的影响。
温度梯度的设置:设定料液比1:25,提取时间20min,超声功率240W,考察在30℃、40℃、50℃、60℃、70℃各温度梯度下,滁菊黄酮提取率的变化。
提取功率的选择:设定料液比1:25,提取温度50℃,提取时间20min,考察功率为240W、300W、360W、420W、480W时,滁菊黄酮提取率的变化。
提取时间的选择:设定提取温度50℃,料液比1:25,超声功率420W,考察时间30min、40min、50min、60min、70min时,滁菊黄酮提取率的变化。
所得结果如下表所示:
正交因素与水平设计
表1
正交实验结果
表2
由上表可知,本发明在滁菊提取液的制备过程中,采用超声水提取黄酮时,滁菊粉与蒸馏水的料液比为1:27,超声功率为380W,提取温度为50℃,提取时间为55min,为最优的提取条件,能有效增加最终药物的黄酮含量,提升治疗效果。
实施例2:
一种明目薰蒸水的制备方法,所述制备方法包括以下步骤:
(1)滁菊提取液的制备:选取优质干燥滁菊,于烘干机中进行烘干处理,再将干燥过的滁菊于粉碎机中进行粉碎处理,得滁菊粉,将滁菊粉加入蒸馏水中,采用超声水提法进行黄酮提取,再经抽滤和冷却后得到滁菊提取液;
(2)金银花提取液的制备:将干燥的金银花经研磨机研磨得金银花粗粉,加入15倍体积份数的蒸馏水常温下进行浸泡,后再于水浴加热的情况下浸泡70min,进行抽滤,所得滤渣同条件下再次浸泡抽滤,合并两次所得滤液,将滤液静置后过滤,将滤液浓缩至原加入蒸馏水体积的2/3,得金银花提取液;
(3)薄荷水提取液的制备:取优质薄荷加入10倍体积份数的蒸馏水,在密闭环境下水浴加热保温一段时间,再将其于大火上煮至沸腾,后转小火煎煮,趁热抽滤,所得澄清液为薄荷水提取液;
(4)熏蒸水制备:将滁菊提取液浓缩至金银花提取液等体积后,与金银花提取液和薄荷水提取液混合,加稀氨水调节PH至8.0,再水浴加热除氨水调PH至6.0,后向其中加入硼砂和硼酸,搅拌均匀后,在灭菌锅中灭菌70min,将所得溶液进行分装,即得到本发明明目薰蒸水。
其中,步骤(1)中滁菊于烘干机中烘干的温度为50℃,烘干时间为1h,滁菊研磨后的粉末需过40目筛;滁菊提取液的制备过程中,滁菊进行超声水提取黄酮时,滁菊粉与蒸馏水的料液比为1:27,超声功率为380W,提取温度为50℃,提取时间为55min;步骤(2)中金银花粗粉与蒸馏水混合在常温下浸泡的时间为24h,水浴加热的温度为75℃;步骤(3)中,水浴加热的温度为70℃,加热的时间为30min,后期小火煎煮的时间为10min;步骤(4)中滁菊提取液、金银花提取液、薄荷水提取液、硼砂和硼酸的质量比为20∶20∶10∶1.3∶5。
实施例3:
对上述实施例2所得熏蒸水进行检测:
(1)性状检测:实施例2所得熏蒸水为浅黄色澄清液体,味微苦气清香。
(2)酸碱度检测:实施例2所得熏蒸水PH为6.0,适合眼部及皮肤局部给药。
(3)粒度检测:将实施例2所得薰蒸水强烈振摇后,用胶头滴管吸取适量滴在载玻片上,涂制3片,依据粒度和粒度分布测定法测定,结果每个涂片中大于50μm的粒子没有超2个,没有检出大于90μm的粒子。
(4)沉降体积比检测:取实施例2所得薰蒸水50ml于具塞量筒量内,密塞,振荡1分钟,记录液面的初始高度HO,静置3小时后记录液面高度H,沉降体积比=H/HO,计算得到沉降比为0.976≧0.90,符合规定。
(5)无菌检查:按照药典四部(通则1101)检查,符合规定。
(6)主药黄酮含量测定:精密量取该实施例2所得薰蒸水1.0mL各三份稀释250倍,在紫外分光光度计下测吸光度平为0.251,根据标准曲线y=0.0189x-0.0187(R2=0.9966)算得x=3.56mg/mL,即含量为178.5mg/瓶[10-11]。
(7)刺激性实验:随机邀请二十位同学尝试连续用实施例2所得薰蒸水一周,未见任何不良反应。
(8)药效感官试验:随机邀请四十三位同学参与本次产品体验,综合四十三位同学的感官,本熏蒸水能提神醒目,缓解眼睛干涩、疲劳等作用。
综上所述,本发明安全环保,无不良作用和有害成分,并且适用于眼部疲劳和各类眼科病症。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括所述要素的过程、方法、物品或者设备中还存在另外的相同要素。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (6)
1.一种明目薰蒸水的制备方法,其特征在于,所述制备方法包括以下步骤:
(1)滁菊提取液的制备:选取优质干燥滁菊,于烘干机中进行烘干处理,再将干燥过的滁菊于粉碎机中进行粉碎处理,得滁菊粉,将滁菊粉加入蒸馏水中,采用超声水提法进行黄酮提取,再经抽滤和冷却后得到滁菊提取液;
(2)金银花提取液的制备:将干燥的金银花经研磨机研磨得金银花粗粉,加入15倍体积份数的蒸馏水常温下进行浸泡,后再于水浴加热的情况下浸泡70min,进行抽滤,所得滤渣同条件下再次浸泡抽滤,合并两次所得滤液,将滤液静置后过滤,将滤液浓缩至原加入蒸馏水体积的2/3,得金银花提取液;
(3)薄荷水提取液的制备:取优质薄荷加入10倍体积份数的蒸馏水,在密闭环境下水浴加热保温一段时间,再将其于大火上煮至沸腾,后转小火煎煮,趁热抽滤,所得澄清液为薄荷水提取液;
(4)熏蒸水制备:将滁菊提取液浓缩至金银花提取液等体积后,与金银花提取液和薄荷水提取液混合,加稀氨水调节PH至8.0,再水浴加热除氨水调PH至6.0,后向其中加入硼砂和硼酸,搅拌均匀后,在灭菌锅中灭菌70min,将所得溶液进行分装,即得到本发明明目薰蒸水。
2.根据权利要求1所述的一种明目薰蒸水的制备方法,其特征在于:步骤(1)中滁菊于烘干机中烘干的温度为50℃,烘干时间为1h,滁菊研磨后的粉末需过40目筛。
3.根据权利要求1所述的一种明目薰蒸水的制备方法,其特征在于:滁菊提取液的制备过程中,滁菊进行超声水提取黄酮时,滁菊粉与蒸馏水的料液比为1:27,超声功率为380W,提取温度为50℃,提取时间为55min。
4.根据权利要求1所述的一种明目薰蒸水的制备方法,其特征在于:步骤(2)中金银花粗粉与蒸馏水混合在常温下浸泡的时间为24h,水浴加热的温度为75℃。
5.根据权利要求1所述的一种明目薰蒸水的制备方法,其特征在于:步骤(3)中,水浴加热的温度为70℃,加热的时间为30min,后期小火煎煮的时间为10min。
6.根据权利要求1所述的一种明目薰蒸水的制备方法,其特征在于:步骤(4)中滁菊提取液、金银花提取液、薄荷水提取液、硼砂和硼酸的质量比为20∶20∶10∶1.3∶5。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810990923.4A CN109200089A (zh) | 2018-08-28 | 2018-08-28 | 一种明目薰蒸水的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810990923.4A CN109200089A (zh) | 2018-08-28 | 2018-08-28 | 一种明目薰蒸水的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109200089A true CN109200089A (zh) | 2019-01-15 |
Family
ID=64986101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810990923.4A Pending CN109200089A (zh) | 2018-08-28 | 2018-08-28 | 一种明目薰蒸水的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109200089A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793786A (zh) * | 2012-08-26 | 2012-11-28 | 李金金 | 一种防眼疲劳的滴眼液 |
CN102793244A (zh) * | 2012-08-11 | 2012-11-28 | 安徽科技学院 | 一种复合滁菊保健饮料制备方法 |
CN103125681A (zh) * | 2011-11-23 | 2013-06-05 | 汤汉忠 | 一种去火茶的制作方法 |
CN107929356A (zh) * | 2017-12-28 | 2018-04-20 | 龙欢乐 | 眼药水及其制备方法和应用 |
-
2018
- 2018-08-28 CN CN201810990923.4A patent/CN109200089A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103125681A (zh) * | 2011-11-23 | 2013-06-05 | 汤汉忠 | 一种去火茶的制作方法 |
CN102793244A (zh) * | 2012-08-11 | 2012-11-28 | 安徽科技学院 | 一种复合滁菊保健饮料制备方法 |
CN102793786A (zh) * | 2012-08-26 | 2012-11-28 | 李金金 | 一种防眼疲劳的滴眼液 |
CN107929356A (zh) * | 2017-12-28 | 2018-04-20 | 龙欢乐 | 眼药水及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
刘昭坤等: "中药熏洗治疗急性流行性结膜炎", 《新中医》 * |
王洪云: "中药雾化熏眼对促进病毒性角膜炎恢复的效果观察", 《中国中医急症》 * |
董洪震等: "中药熏眼联合玉屏风散对单纯疱疹性病毒性角膜炎血清及泪液相关指标的影响 ", 《云南中医学院学报》 * |
谷万章: "眼科常用中药杂记 ", 《航空航天医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101843662B (zh) | 一种预防和治疗视疲劳的中药组合物 | |
CN104645107A (zh) | 一种中药组合物及其制备方法和应用 | |
CN108042653A (zh) | 一种抗疲劳醒神植物棉片及其制备工艺 | |
CN104306678A (zh) | 一种治疗产后抑郁的中药制剂及制备方法 | |
CN104042797A (zh) | 一种用于制备治疗心血管疾病的艾维心口服液及制备方法 | |
CN109200089A (zh) | 一种明目薰蒸水的制备方法 | |
CN105616839B (zh) | 一种具有抗抑郁作用的中药药效组分复方 | |
CN107412552A (zh) | 一种能够治疗儿童近视的护眼液及其制备方法 | |
CN104721508B (zh) | 一种治疗上呼吸道感染的药物组合物及制备方法 | |
JP2007204465A (ja) | 目の疲れを取る薫蒸法 | |
CN103463244A (zh) | 一种从月季花中提取降糖物质的方法及其应用 | |
CN107648397B (zh) | 一种用于治疗肝肾阴虚型的中药组合物及其制备方法和应用 | |
CN103316260B (zh) | 用于治疗手足癣的按摩膏 | |
CN105727022A (zh) | 一种含有中草药的药酒 | |
CN105997762A (zh) | 祛痘美容液 | |
CN107929356B (zh) | 眼药水及其制备方法和应用 | |
CN101874843B (zh) | 一种治疗流行性感冒的药物 | |
CN105535115A (zh) | 一种降血糖中药、制备方法及用途 | |
CN105919907A (zh) | 中药眼霜制作方法及其眼霜 | |
CN104689107A (zh) | 一种用于治疗近视眼的中药配方及其制备方法 | |
CN101474267B (zh) | 一种治疗精神衰弱失眠心烦的药物 | |
CN105012484B (zh) | 一种治疗化脓性鼻窦炎的药物制剂及其制备方法 | |
CN110269895A (zh) | 一种含鲜中药的视力康复中药组合物及其制备方法、制剂 | |
CN103751627A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN103784825A (zh) | 一种穿虎痛风合剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |